Recce Pharmaceuticals Receives positive safety data from second cohort of Phase I Clinical Trial
- Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327)
- R327 is designed to treat serious bacterial infections including sepsis.
- The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327
- An independent safety committee has approved an increase in dosage to 500mg in the third cohort
- Shares were trading 2.69 per cent higher today at $1.34 at the end of the trading day
